跳至主要内容
临床试验/NCT05756881
NCT05756881终止不适用

A Randomised Double-blind Placebo-controlled Study on the Effects of Topical Palm Tocotrienols on Blemish-prone Skin

Universiti Sains Malaysia2 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2023年2月15日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
5
试验地点
2
主要终点
Proportion of participants with at least 50% reduction in numbers of acne lesion or at least 2 grade improvement according to CASS from baseline

研究概览

简要总结

A single-center, double-blind, randomised, placebo-controlled parallel-group study.

Selected subjects will be randomised into active and control groups in a ratio of 1:1. Investigational products assigned will be applied on the facial skin as part of daily skin care routine. The effects will be observed during the 12-weeks of use.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy individuals, aged 18 years and above
  • Fitzpatrick skin type II to IV
  • Blemish-prone skin with acne of severity grade 2 or 3 based on Comprehensive Acne Severity Scale (CASS)

排除标准

  • Has a history of chronic drug or alcohol abuse
  • Is a current smoker
  • History of severe allergic reactions to topical products or vitamin E
  • Participant with severe and uncontrollable comorbidities (including but not limited to e.g. diabetes, hypertension, kidney failure)
  • Pregnant, breastfeeding, or planning pregnancy
  • Participant with known skin conditions (including but not limited to e.g. sensitive skin, eczema and diseased skin e.g. contact dermatitis), uncontrolled medical conditions, or any other condition that could interfere with the study evaluations or increase risk to the participant (such as polycystic ovary syndrome and contact dermatitis)
  • Participant with compromised/broken skin, tattoos, scarring, excessive hair growth, very uneven skin tone, or other conditions that would interfere with evaluations or increase risk
  • Participation in another study within 4 weeks of screening visit
  • Has severe acne or acne conglobata
  • Use of systemic treatment for acne such as isotretinoin, contraceptive pills, or spironolactone within 4 weeks of screening visit
  • Use of topical treatments like antibiotics, corticosteroids, benzoyl peroxide, azelaic acid, salicylic acid, alpha hydroxy acids (AHAs), vitamins A (retinol) or C (ascorbic acid) or their analogs or derivatives and other anti-inflammatory drugs within 2 weeks of screening visit
  • Use of scrub, alpha-hydroxy acid (AHA), skin irritant products in the 2 days before study treatment start
  • Participant with active bacterial/fungal/viral skin infections or susceptibility to such infections within 2 weeks of Screening visit
  • Use oral antibiotics

结局指标

主要结局

Proportion of participants with at least 50% reduction in numbers of acne lesion or at least 2 grade improvement according to CASS from baseline

时间窗: 18 Week

Acne lesion count

次要结局

  • CASS assessment(18 Week)
  • The percent change from baseline in global face total lesion count.(18 Week)
  • Acne lesion counts for the total global face and total lesion counts(18 Week)
  • Survey (CADI)(18 Week)
  • The percent change from baseline in sebum, skin pH, hydration and erythema index(18 Week)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Goh Choon Fu

Principal Investigator

Universiti Sains Malaysia

研究点 (2)

Loading locations...

相似试验